Should fraction flow reserve be considered an important decision-making tool to stratify patients with stable coronary artery disease for percutaneous coronary intervention? A meta-analysis
Pravesh Kumar Bundhun, MD\textsuperscript{a}, Chakshu Gupta, MBBS\textsuperscript{b}, Feng Huang, MD\textsuperscript{c}\textsuperscript{*}

Abstract
Background: Nowadays, fraction flow reserve (FFR) is being discussed in every percutaneous coronary intervention (PCI) capable hospitals. Owing to recent development in the medical field, FFR-guided PCI should be able to find a place in Interventional Cardiology. At present, the importance of FFR to stratify patients who require PCI has seldom systematically been investigated. In this analysis, we aimed to compare the major adverse cardiac events (MACEs) mainly in patients with stable coronary artery disease (CAD) to whom PCI was recommended and deferred respectively based on the FFR value.

Methods: Electronic databases were searched for studies comparing FFR-recommended versus FFR-deferred coronary stenting. Long-term MACEs, mortality, and myocardial infarction (MI) were considered as the clinical endpoints in this analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated and the analyses were carried out by the latest version of the RevMan software.

Results: A total number of 1753 patients (670 patients were revascularized, whereas 1083 patients were deferred from revascularization based on the FFR value) were analyzed. Current results showed MACEs and MI were significantly higher in the FFR-recommended PCI group with OR 1.34 (95% CI: 1.05–1.72; \(P = .02\)) and OR 1.73 (95% CI: 1.19–2.51; \(P = .004, I^2 = 0\%\)), respectively. However, mortality was similarly manifested with OR 1.23 (95% CI: 0.92–1.63; \(P = .16, I^2 = 0\%\)).

Conclusion: Significantly higher MACEs were observed in patients to whom PCI was recommended compared to those patients who were deferred from undergoing PCI based on the FFR values. Therefore, FFR might indeed be an important decision-making procedural tool, which should be used to stratify stable CAD patients with an advanced disease and who are qualified candidates for PCI. Further research should confirm this hypothesis.

Abbreviations: FFR = fraction flow reserve, MACEs = major adverse cardiac events, MI = myocardial infarction, PCI = percutaneous coronary intervention.

Keywords: Fraction flow reserve, major adverse cardiac events, percutaneous coronary intervention.
1. Introduction

Nowadays, fraction flow reserve (FFR) is being discussed in every percutaneous coronary intervention (PCI) capable hospitals. Owing to recent development in the medical field, FFR guided PCI should be able to find a place in Interventional Cardiology.

In coronary artery diseases (CAD), FFR can provide a functional evaluation or assessment of the obstructed artery. With reference to the repeated noninvasive stress testing, the FFR threshold to differentiate or to recognize a clinically significant lesion level ischemia is 0.75. Nevertheless, to expand measurement sensitivity to exclude the presence of functionally significant stenosis, a threshold of 0.80 has recently been adopted by the European Society of Cardiology (ESC). [3]

However, when a decision is to be taken with the involvement of FFR, other clinical factors should also be taken into consideration. An FFR value lying between 0.76 and 0.80 was considered to be in the “grey zone.” Even if clinical practice guideline has adopted a cutoff value of ≤0.80, several previous studies have considered FFR value of ≤0.75 as the cutoff value.

At present, the importance of FFR to stratify patients who need to be revascularized with PCI has seldom systematically been investigated. In this analysis, we aimed to compare the major adverse cardiac events (MACEs) mainly in patients with stable CAD to whom PCI was recommended or deferred based on the FFR value.

2. Methods

2.1. Data sources and search strategy

Studies comparing FFR-recommended versus FFR-deferred coronary stenting were searched from electronic databases (MEDLINE: database of medical articles, EMBASE, and the Cochrane library) by typing the terms “fraction flow reserve and percutaneous coronary intervention.” The abbreviations “FFR and PCI” as well as the terms “FFR-deferred angiography, deferred” were also used. In addition, reference lists of selective articles were also checked for relevant studies. This search strategy was only based on articles, which were published in English. Publications which were available in Chinese or other non-English languages were not considered relevant.

2.2. Inclusion and exclusion criteria

Studies were included if:

1. They were randomized trials or observational studies comparing FFR-recommended versus FFR-deferred PCI.
2. They had a follow-up period of >1 year.
3. MACEs, myocardial infarction (MI), or mortality were reported among their clinical endpoints.

Studies were excluded if they were meta-analyses, case studies, and letter to editors even if they were associated with FFR-guided PCI.

1. They only compared FFR-guided with non-FFR-guided angiography or PCI.
2. They had a short-term follow-up period of <1 year.
3. They did not report MACEs, MI, or mortality among their clinical endpoints.
4. They were duplicated studies.

2.3. Type of participants, outcomes, definitions, and follow-up

Those who participated in this analysis comprised of patients with stable CAD, intermediate, or moderate coronary stenosis as shown in Table 1.

The outcomes which were analyzed included:

1. MACEs (mortality, MI, and repeated revascularization)
2. Mortality (all-cause death/cardiac death)
3. MI

This analysis had a long-term follow-up period of >1 year. The clinical outcomes which were reported in each study, as well as the corresponding follow-up periods, were listed in Table 2.

2.4. Data extraction and review

The first (PKB) and the second authors (CG) individually assessed the titles and abstracts which were presented during the search strategy, and selected the full-text articles, which were qualified for this analysis. The type of study which was reported, the total number of patients in the FFR-recommended PCI group, and the

### Table 1

| Studies            | Types of participants                                                                 | Stented or not with PCI                                                                 |
|--------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Berger et al (2005)| MVCAD                                                                                | FFR-recommended patients were treated by PCI, FFR-deferred treated medically after angiography |
| Li et al (2013)    | General population with CAD                                                           | PCI performed only in FFR-recommended patients, but not performed in FFR-deferred group |
| Misaka et al (2011)| General population with stable intermediate CAD                                        | PCI was performed in patients with FFR recommendation, whereas no revascularization was performed in FFR deferred group |
| Oud et al (2010)   | General population with CAD                                                           | PCI or CABG was performed in patients with FFR recommendation, whereas no revascularization was performed in FFR deferred group |
| Miller et al (2012)| General population with CAD                                                           | PCI or CABG was performed in patients with FFR recommendation, whereas medical therapy performed in FFR-deferred patients |
| Yamashita et al (2015)| Gray zone FFR. General population with moderate CAD                                      | PCI was performed in patients with FFR recommendation, whereas no revascularization was performed in FFR-deferred group |
| DEFER DES [12]     | General population with intermediate CAD                                               | PCI was performed in patients with FFR recommendation, whereas no revascularization was carried out in FFR-deferred patients |

CABG = coronary artery bypass surgery; CAD = coronary artery disease; FFR = fraction flow reserve; LMCAS = left main coronary artery stenosis; MVCAD = multivessel coronary artery disease; PCI = percutaneous coronary intervention.
3. Results

3.1. Searched outcomes

Two hundred and forty-six (246) articles were obtained from electronic databases. After a careful assessment and review of the titles and abstracts, 216 articles were not related to the idea of this analysis and were directly eliminated. In addition, another 10 articles were eliminated as they were duplicates of the studies which were initially considered relevant. Twenty full-text articles were assessed for eligibility. Ten articles were further eliminated as they compared FFR-guided with non-FFR-guided coronary angiography. Another 3 articles were eliminated as they were meta-analyses. Finally, 7 articles[6–12] were confirmed for this meta-analysis (Fig. 1).

3.2. General features of the studies

A total number of 1753 patients (670 patients were revascularized, whereas 1083 patients were deferred from revascularization based on the FFR value) were analyzed. Table 3 summarized the main features of the studies which were included in this analysis.

3.3. Baseline features of the patients

The baseline features of the patients have been summarized in Table 4.

Mean age was reported in years. According to Table 4, no significant differences were observed in baseline features (except for dyslipidemia which was lower in the FFR-deferred group) among patients who were classified in the FFR-recommended PCI group and patients to whom PCI was deferred.

3.4. Major adverse cardiac events which were reported in patients to whom PCI was recommended versus patients to whom PCI was deferred based on the FFR value

The results of this analysis have been represented in Table 5.

In this analysis, a few studies also reported patients who were revascularized by coronary artery bypass surgery (CABG) or PCI based on the FFR value. Because the total number of patients who underwent revascularization with PCI or CABG were combined in 2 studies,[9,10] and the respective data could not be separated, this analysis was carried out twice (once without those 2 studies and another time including both studies).

MACEs and MI were significantly higher in those patients who underwent PCI with OR 1.34 (95% CI: 1.05–1.72; P = .02) and OR 1.96 (95% CI: 1.25–3.06; P = .003), respectively compared to those patients to whom PCI was deferred based on the FFR value. However, mortality was not significantly different with OR 1.15 (95% CI: 0.83–1.58; P = .40) as shown in Figure 2.

When studies of Oud et al (2010)[9] and Miller et al (2012)[10] were included from the main analysis, MI was still significantly higher in patients to whom PCI/CABG was recommended with OR 1.73 (95% CI 1.19–2.51; P = .004), whereas no significant difference was observed in mortality among patients to whom revascularization was recommended or deferred based on the FFR value with OR 1.23 (95% CI: 0.92–1.63; P = .16) as shown in Figure 3.

As this analysis included different cut-off values of FFR, whereby in some cases, PCI was deferred with an FFR value >0.75 or >0.80, and recommended in patients with an FFR value <0.75 or <0.80, we additionally carried out a selective analysis including only studies, which reported an FFR value of 0.75 as the cutoff point.

This selective analysis also showed MACEs to be significantly higher in the FFR-recommended revascularization group with OR 2.58 (95% CI: 1.30–5.12; P = .007). Mortality and MI were

---

Table 2

| Studies            | Outcomes | Follow-up period | FFR value in PCI-deferred group | FFR value in PCI-recommended group |
|--------------------|----------|-----------------|---------------------------------|-----------------------------------|
| Berger et al (2005)[6] | MACEs    | 29 mo           | >0.75                           | <0.75                             |
| Li et al (2013)[7]  | Death, MI, MACEs | 1–7 y          | >0.80                           | <0.75                             |
| Misaka et al (2011)[8] | Death, MACEs | 53 mo          | ≥0.75                           | <0.75                             |
| Oud et al (2010)    | Death, MI | 22 mo           | ≥0.75                           | <0.75                             |
| Miller et al (2012)[9] | Death, MI   | 5–6 y          | >0.80                           | <0.75                             |
| Yamashita et al (2015)[10] | Death, MI | 7 y            | 0.81–0.85                       | 0.75–0.80                         |
| DEFER DES[11]      | Death, MACEs, MI | 5 y          | ≥0.75                           | <0.75                             |

FFR = fractional flow reserve, MACEs = major adverse cardiac events, MI = myocardial infarction, PCI = percutaneous coronary intervention.
not significantly different with OR 1.01 (95% CI: 0.35–2.95; \( P = .98 \)) and OR 2.01 (95% CI: 0.54–7.50; \( P = .30 \)), respectively as shown in Figure 4.

Sensitivity analysis yielded consistent results. Moreover, there was only little evidence of publication bias based on visually assessing the funnel plots (Fig. 5A and B).

4. Discussion
This is the first systematic review and meta-analysis comparing the long-term MACEs based on patients to whom PCI was recommended or deferred based on the FFR value. Several studies have already shown that FFR-guided angiography is safe and will be beneficial in PCI. However, this current analysis further

| Studies            | Type of study | Patients' enrollment | No. of patients with FFR-recommended revascularization (n) | No. of patients with FFR-deferred revascularization (n) |
|--------------------|---------------|----------------------|------------------------------------------------------------|----------------------------------------------------------|
| Berger et al (2005)  | Observational | 1994–2002            | 113                                                        | 127                                                      |
| Li et al (2013)     | Observational | 2002–2009            | 352                                                        | 613                                                      |
| Misaka et al (2011) | Observational | 2002–2009            | 15                                                         | 29                                                       |
| Oud et al (2010)    | Observational | 2006                 | 49                                                         | 70                                                       |
| Miller et al (2012) | Observational | 2000–2005            | 57                                                         | 94                                                       |
| Yamashita et al (2015) | Observational | —                    | 55                                                         | 65                                                       |
| DEFER DES           | RCT           | 2006–2007            | 29                                                         | 85                                                       |
| Total no. of patients (n) |               |                      | 670                                                        | 1083                                                     |

FFR = fraction flow reserve, RCT = randomized controlled trial.
Table 4
Baseline features of the studies which were included.

| Studies               | Mean age X/Y | Males (%) X/Y | Ht (%) X/Y | Ds (%) X/Y | Cs (%) X/Y | DM (%) X/Y |
|-----------------------|--------------|---------------|------------|------------|------------|------------|
| Berger et al (2005)[6] | —            | —             | —          | —          | —          | —          |
| Li et al (2013)[7]    | 65.8/65.5    | 59.3/69.1     | 78.7/80.2  | 41.0/84.5  | 12.6/13.2  | 27.7/28.7  |
| Misaka et al (2011)[8]| 66.4/66.5    | 75.9/86.7     | 75.9/73.3  | 62.1/53.3  | 48.3/40.0  | 51.7/33.3  |
| Oud et al (2010)      | 64.0/64.0    | 70.0/73.0     | —          | —          | —          | —          |
| Miller et al (2012)[9]| 66.1/63.7    | 96.8/100      | 81.9/87.7  | —          | —          | —          |
| Yamashita et al (2015)[11]| 64.0/62.0 | 86.0/82.0     | 65.0/62.0  | 62.0/73.0  | 40.0/49.0  | 43.0/33.0  |
| DEFER DES[11]         | 62.0/62.0    | 76.0/72.0     | 66.0/64.0  | 69.0/71.0  | 35.0/24.0  | 28.0/26.0  |

Cs = current smoker, DM = diabetes mellitus, Ds = dyslipidemia, Ht = hypertension, X = FFR-recommended PCI, Y = FFR deferred PCI.

Table 5
Results of this analysis.

| Outcomes analyzed | No. of studies involved (n) | OR with 95% CI       | P     | P^2 (%) |
|-------------------|----------------------------|----------------------|-------|---------|
| **Revascularization by PCI only** | |                         |       |         |
| MACEs             | 4                          | 1.34 [1.05–1.72]     | .02   | 42      |
| Mortality         | 4                          | 1.15 [0.83–1.58]     | .40   | 0       |
| MI                | 3                          | 1.96 [1.25–3.06]     | .003  | 0       |
| **Revascularization by PCI or CABG** | |                         |       |         |
| Mortality         | 6                          | 1.23 [0.92–1.63]     | .16   | 0       |
| MI                | 5                          | 1.73 [1.19–2.51]     | .004  | 0       |
| **Using 0.75 as the cutoff value** | |                         |       |         |
| MACEs             | 3                          | 2.58 [1.30–5.12]     | .007  | 0       |
| Mortality         | 3                          | 1.01 [0.35–2.95]     | .98   | 0       |
| MI                | 2                          | 2.01 [0.54–7.50]     | .30   | 0       |

CABG = coronary artery bypass surgery, CI = confidence intervals, MACEs = major adverse cardiac events, MI = myocardial infarction, OR = odds ratios, PCI = percutaneous coronary intervention.

Figure 2. Adverse cardiovascular outcomes observed between FFR-recommended versus FFR-deferred coronary intervention (including patients who were revascularized only by PCI). CI = confidence interval, FFR = fraction flow reserve, PCI = percutaneous coronary intervention.
showed that in all the patients to whom FFR-guided angiography was considered, FFR-recommended PCI indicated an advanced CAD, which could later be associated with a higher risk of MACEs compared to patients to whom PCI was deferred. This hypothesis should be considered a new feature of this analysis. Moreover, being associated with a very low level of heterogeneity among all the subgroups which were analyzed, this study represents another new feature.

Results of this analysis showed a significantly higher rate of MACEs and MI in patients to whom revascularization was recommended based on the FFR value compared to patients to whom revascularization was deferred.

Kim et al[13] showed that FFR-guided PCI was very safe and effective among the 131 patients with multiple intermediate stenosis. Moreover, their study did not show any event related to deferred lesions. The authors also concluded that FFR-guided PCI was valuable for guiding revascularization in patients with intermediate stenosis.

Figure 3. Adverse cardiovascular outcomes observed between FFR-recommended versus FFR-deferred coronary intervention (including patients who were revascularized by PCI or coronary artery bypass surgery). CI = confidence interval, FFR = fraction flow reserve, PCI = percutaneous coronary intervention.

Figure 4. Adverse cardiovascular outcomes observed between FFR-recommended versus FFR-deferred coronary intervention (PCI or CABG using an FFR value 0.75 as the cutoff point). CI = confidence interval, FFR = fraction flow reserve, PCI = percutaneous coronary intervention.
PCI could decrease unnecessary interventions and maximize the benefits of PCI with drug-eluting stents.

Results of the DEFER (FFR to Determine Appropriateness of Angioplasty in Moderate Coronary Stenoses) study[14] showed that every 0.01 decrease in FFR value was associated with a significantly higher rate of MI in patients with acute coronary syndrome (among 1872 patients who underwent FFR assessment between the years 2002 and 2012).

However, the current analysis showed a significantly higher rate of MACEs and MI in the FFR-recommended PCI group, whereas the result for mortality was not significant.

Pereira et al[15] assessed the long-term follow-up of patients with deferred coronary intervention guided by measurement of FFR. They showed MACEs-free survival to be 97.8% during a follow-up period of 1 year among the 232 patients who were involved. In their study, patients had intermediate CAD (50%–70% of coronary obstruction) and they were deferred for coronary intervention based on an FFR value <0.80 as adopted by the ESC.

In addition, Dominguez-Franco et al[16] assessed the long-term prognosis in diabetic patients to whom revascularization was deferred following FFR assessment. PCI was deferred in 136 patients with an FFR value ≥0.75 and in their study, the authors concluded that deferring PCI in diabetic patients with moderately severe coronary artery obstruction having an FFR of ≥0.75 was considered safe and was not associated with long-term MACEs.

However, other research showed diabetes mellitus to be independently associated with target vessel failure when compared to nondiabetic patients with deferred FFR.[17]

This current analysis showed that significantly higher major adverse events were observed in patients to whom PCI was recommended compared to patients to whom PCI was deferred based on the FFR value showing that the latter could be considered as an important decision-making tool to predict whether a coronary disease is severe enough to consider revascularization by PCI, thus selecting those patients with mild CAD who are at low risk for MACEs and who do not require revascularization.

However, further research should focus on the disadvantage of FFR, if present.

Recently, Bundhun et al[18] showed FFR-guided PCI not to be associated with significantly increased adverse outcomes when compared to angiography-guided PCI. Inspired by their research, we carried out this analysis which was based on patients to whom PCI was recommended or deferred based on the FFR value.

This current analysis consisted of data which were obtained mainly from observation studies (except DEFER DES trial) because there was only 1 randomized trial that satisfied the inclusion and exclusion criteria of this study. However, the best part of this analysis (positive aspect) was the involvement of a very low level of heterogeneity among all the subgroups which were analyzed.

Even if this analysis represents a completely new idea in clinical medicine, it also has several limitations. First of all, because of the limited number of patients that were analyzed, this study might not provide robust results. In addition, study of Berger et al (2005) did not indicate the number of patients in the FFR-recommended and FFR-deferred groups; therefore, when carrying out the statistical analysis, the number of lesions were included instead. Moreover, even if all the studies which were involved reported a long-term follow-up period, the period interval was different in each study. This might also have affected the results of this analysis. The inclusion of data from observational cohorts could also represent a limitation. In addition, the revascularization procedures, the severity of CAD, and the postinterventional medications could all have had an impact on the results. At last, even if this analysis was based mainly on patients with stable CAD, 1 study which was also included in this analysis consisted of patients with multivessel CAD.

5. Conclusion

Significantly higher MACEs were observed in patients to whom PCI was recommended compared to those patients who were deferred from undergoing PCI based on the FFR values. Therefore, FFR might indeed be an important decision-making procedural tool which should be used to stratify stable CAD patients with an advanced disease and who are qualified candidates for PCI. Further research should confirm this hypothesis.

References

[1] Pijls NH, D Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 1996;334:1703–8.
[2] Bech GJ, De Bruyne B, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary-stenosis: a randomized trial. Circulation 2001;103:2928–34.
[3] Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213–24.

[4] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

[5] Higgins JPT, Altman DG, Higgins JPT, Green S. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 2008;Wiley, 187–241.

[6] Berger A, Botman KJ, MacCarthy PA, et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol 2005;46:438–42.

[7] Li J, Elrashidi MY, Flammer AJ, et al. Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J 2013;34:1375–83.

[8] Misaka T, Kunii H, Mizukami H, et al. Long-term clinical outcomes after deferral of percutaneous coronary intervention of intermediate coronary stenoses based on coronary pressure-derived fractional flow reserve. J Cardiol 2011;58:32–7.

[9] Oud N, Marques KM, Bronzuwaer JG, et al. Patients with coronary stenosis and a fractional flow reserve of ≥0.75 measured in daily practice at the VU University Medical Center. Neth Heart J 2010;18:402–7.

[10] Miller LH, Toklu B, Rauch J, et al. Very long-term clinical follow-up after fractional flow reserve-guided coronary revascularization. J Invasive Cardiol 2012;24:309–13.

[11] Yamashita J, Tanaka N, Shiundo N, et al. Seven-year clinical outcomes of patients with moderate coronary artery stenosis after deferral of revascularization based on gray-zone fractional flow reserve. Cardiovasc Interv Ther 2015;30:209–15.

[12] Park SH, Joon KH, Lee JM, et al. Long-term clinical outcomes of fractional flow reserve-guided versus routine drug-eluting stent implantation in patients with intermediate coronary stenosis: five-year clinical outcomes of DEFER-DESTrial. Circ Cardiovasc Interv 2015;8:e002442.

[13] Kim HL, Koo BK, Nam CW, et al. Clinical and physiological outcomes of fractional flow reserve-guided percutaneous coronary intervention in patients with serial stenoses within one coronary artery. JACC Cardiovasc Interv 2012;5:1013–8.

[14] Masi S, Depta JP, Novak E, et al. Association of lower fractional flow reserve values with higher risk of adverse cardiac events for lesions deferred revascularization among patients with acute coronary syndrome. J Am Heart Assoc 2015;4:e002172.

[15] Vidalonga Pereira L, Pereira H, Vinhas H, et al. Long-term follow-up of patients with deferred coronary intervention guided by measurement of fractional flow reserve. Rev Port Cardiol 2013;32:885–91.

[16] Domínguez-Franco AJ, Jimenez-Navarro MF, Munoz-Garcia AJ, et al. Long-term prognosis in diabetic patients in whom revascularization is deferred following fractional flow reserve assessment. Rev Esp Cardiol 2008;61:352–9.

[17] Kennedy MW, Kaplan E, Hermanides RS, et al. Clinical outcomes of deferred revascularization using fractional flow reserve in patients with and without diabetes mellitus. Cardiovasc Diabetol 2016;15:100.

[18] Bundhun PK, Yanamala CM, Huang F. Comparing the adverse clinical outcomes associated with fraction flow reserve-guided versus angiography-guided percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2016;16:249.